NASDAQ: ALLRAllarity Therapeutics Inc Stock
$1.20+0.01 (+0.84%)
Updated Jan 27, 2026
ALLR Priceļ»æ
$1.20
Fair Value Price
N/A
Market Capļ»æ
$18.97M
52 Week Lowļ»æ
$0.61
52 Week Highļ»æ
$2.35
P/Eļ»æ
0.13x
P/Bļ»æ
1.58x
P/Sļ»æ
N/A
PEGļ»æ
N/A
Dividend Yieldļ»æ
N/A
Revenueļ»æ
$0.00
Earningsļ»æ
-$15.31M
Gross Marginļ»æ
N/A
Operating Marginļ»æ
N/A
Profit Marginļ»æ
N/A
Debt to Equityļ»æ
0.73
Operating Cash Flow
-$15M
Betaļ»æ
0.97
Next Earningsļ»æ
N/A
Ex-Dividendļ»æ
N/A
Next Dividendļ»æ
N/A
ALLR Overview
Allarity Therapeutics is a biopharma company developing oncology products and drugs for the personalized treatment of cancer. The company uses Drug Response Predictor (DRPĀ®) technology to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures. Its pipeline products include Dovitinib, Stenoparib, Ixempra, and other formulations. Allarity was incorporated in 2004 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALLR's potential to beat the market
- ALLR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALLR
RankedUnranked of 483
RankedUnranked of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $336.16 | A | |
| $6.76 | A | |
| $5.30 | A |
Be the first to know about important ALLR news, forecast changes, insider trades & much more!
ALLR News
Overview
Due Diligence Score
ā
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALLR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALLR was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Valueļ»æ Valuation
ALLR is good value based on its earnings relative to its share price (0.13x), compared to the US market average (41.71x)
P/E vs Marketļ»æ Valuation
ALLR is good value based... subscribe to Premium to read more.
P/E vs Industryļ»æ Valuation
There are 30 more ALLR due diligence checks available for Premium users.
Valuation
ALLR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.13x
Industry
162.68x
Market
41.71x
ALLR is good value based... subscribe to Premium to read more.
P/E vs Industryļ»æ Valuation
ALLR is good value based... subscribe to Premium to read more.
P/E vs Marketļ»æ Valuation
ALLR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.58x
Industry
5.64x
ALLR is good value based... subscribe to Premium to read more.
P/B vs Industryļ»æ Valuation
ALLR's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.8M
Profit Margin
0%
ALLR's cash burn is expected... subscribe to Premium to read more.
Interest Coverageļ»æ Financials
Assets to liabilities
Assets
$20.8M
Liabilities
$8.8M
Debt to equity
0.73
ALLR's short-term assets ($20.47M) exceed... subscribe to Premium to read more.
Short-term Liabilitiesļ»æ Financials
ALLR's short-term assets ($20.47M) exceed... subscribe to Premium to read more.
Long-term Liabilitiesļ»æ Financials
ALLR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equityļ»æ Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
$2.3M
ALLR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverageļ»æ Financials
ALLR vs Biotech Stocks
Allarity Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.